Where Europe’s ‘BeNeLuxA’ Joint Pricing Pilot May Have Gone Wrong
A more innovative approach to pricing and reimbursement arrangements is needed in the pilot BeNeLuxA joint pricing negotiations, says Eurordis head Yann Le Cam. The Netherlands and Belgium are expected to re-start the negotiations soon after a “time-out” period.
You may also be interested in...
In a BeNeLuxA first, Belgium and the Netherlands have reached an agreement with Biogen to reimburse rare disease treatment Spinraza after joint health technology assessment and pricing negotiations.
Slovenia has joined the Valletta group, with Croatia set to follow. Meanwhile, Ireland has formally signaled its interest in joining the BeNeLuxA collaboration.
The BeNeLuxA coalition shows that “resetting the balance of power” is possible to give governments more clout in pricing negotiations, says the European Public Health Alliance.